Characterization of cytokeratin 20 expression in pancreatic and colorectal cancer

Stefan Wildi, Jörg Kleeff, Haruhisa Maruyama, Christoph A. Maurer, Helmut Friess, Markus W. Büchler, Arthur D. Lander, Murray Korc

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Cytokeratin 20 belongs to the epithelial subgroup of the intermediate filament family. Because of its restricted range of expression in humans, it has become an important tool for detecting and identifying metastatic cancer cells by immunohistochemistry and by PCR analysis. Despite its widespread diagnostic use in colorectal cancer and occasional use in pancreatic cancer, little is known about the expression of CK 20 in these tumors in vivo. Therefore, in the present study we characterized CK 20 expression in pancreatic and colorectal cancer by comparison with its expression in the normal pancreas and colon. Tissue samples from 24 patients with pancreatic cancer and from 41 patients with colorectal cancer were examined for CK 20 expression by Northern blot analysis, immunohistochemistry, and in situ hybridization. CK 20 expression was observed in the cancer cells of both cancer types. A subgroup of the pancreatic cancers exhibited a 3.2-fold increase in CK 20 mRNA by comparison with respective normal controls. In contrast, colon cancers underexpressed CK 20 mRNA by comparison with the respective controls. In the normal tissues, CK 20 immunoreactivity was relatively faint and sparse in the pancreatic ductal cells but intense and abundant in the apical portions of the colonic mucosa. CK 20 immunoreactivity was also evident in the ductal cells from the chronic pancreatitis-like lesions adjacent to the cancer cells. Furthermore, distant metastases from pancreas carcinomas exhibited strong CK 20 immunoreactivity. It is concluded that CK 20 is overexpressed in pancreatic cancer and that it can serve as an excellent marker for metastatic pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)2840-2847
Number of pages8
JournalClinical Cancer Research
Volume5
Issue number10
StatePublished - Oct 1999
Externally publishedYes

Fingerprint

Keratin-20
Pancreatic Neoplasms
Colorectal Neoplasms
Neoplasms
Pancreas
Immunohistochemistry
Messenger RNA
Intermediate Filaments
Chronic Pancreatitis
Northern Blotting
Colonic Neoplasms
In Situ Hybridization
Colon
Mucous Membrane
Neoplasm Metastasis
Carcinoma
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wildi, S., Kleeff, J., Maruyama, H., Maurer, C. A., Friess, H., Büchler, M. W., ... Korc, M. (1999). Characterization of cytokeratin 20 expression in pancreatic and colorectal cancer. Clinical Cancer Research, 5(10), 2840-2847.

Characterization of cytokeratin 20 expression in pancreatic and colorectal cancer. / Wildi, Stefan; Kleeff, Jörg; Maruyama, Haruhisa; Maurer, Christoph A.; Friess, Helmut; Büchler, Markus W.; Lander, Arthur D.; Korc, Murray.

In: Clinical Cancer Research, Vol. 5, No. 10, 10.1999, p. 2840-2847.

Research output: Contribution to journalArticle

Wildi, S, Kleeff, J, Maruyama, H, Maurer, CA, Friess, H, Büchler, MW, Lander, AD & Korc, M 1999, 'Characterization of cytokeratin 20 expression in pancreatic and colorectal cancer', Clinical Cancer Research, vol. 5, no. 10, pp. 2840-2847.
Wildi S, Kleeff J, Maruyama H, Maurer CA, Friess H, Büchler MW et al. Characterization of cytokeratin 20 expression in pancreatic and colorectal cancer. Clinical Cancer Research. 1999 Oct;5(10):2840-2847.
Wildi, Stefan ; Kleeff, Jörg ; Maruyama, Haruhisa ; Maurer, Christoph A. ; Friess, Helmut ; Büchler, Markus W. ; Lander, Arthur D. ; Korc, Murray. / Characterization of cytokeratin 20 expression in pancreatic and colorectal cancer. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 10. pp. 2840-2847.
@article{5f8c375bf11d42069996d48e27a77b05,
title = "Characterization of cytokeratin 20 expression in pancreatic and colorectal cancer",
abstract = "Cytokeratin 20 belongs to the epithelial subgroup of the intermediate filament family. Because of its restricted range of expression in humans, it has become an important tool for detecting and identifying metastatic cancer cells by immunohistochemistry and by PCR analysis. Despite its widespread diagnostic use in colorectal cancer and occasional use in pancreatic cancer, little is known about the expression of CK 20 in these tumors in vivo. Therefore, in the present study we characterized CK 20 expression in pancreatic and colorectal cancer by comparison with its expression in the normal pancreas and colon. Tissue samples from 24 patients with pancreatic cancer and from 41 patients with colorectal cancer were examined for CK 20 expression by Northern blot analysis, immunohistochemistry, and in situ hybridization. CK 20 expression was observed in the cancer cells of both cancer types. A subgroup of the pancreatic cancers exhibited a 3.2-fold increase in CK 20 mRNA by comparison with respective normal controls. In contrast, colon cancers underexpressed CK 20 mRNA by comparison with the respective controls. In the normal tissues, CK 20 immunoreactivity was relatively faint and sparse in the pancreatic ductal cells but intense and abundant in the apical portions of the colonic mucosa. CK 20 immunoreactivity was also evident in the ductal cells from the chronic pancreatitis-like lesions adjacent to the cancer cells. Furthermore, distant metastases from pancreas carcinomas exhibited strong CK 20 immunoreactivity. It is concluded that CK 20 is overexpressed in pancreatic cancer and that it can serve as an excellent marker for metastatic pancreatic cancer.",
author = "Stefan Wildi and J{\"o}rg Kleeff and Haruhisa Maruyama and Maurer, {Christoph A.} and Helmut Friess and B{\"u}chler, {Markus W.} and Lander, {Arthur D.} and Murray Korc",
year = "1999",
month = "10",
language = "English (US)",
volume = "5",
pages = "2840--2847",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Characterization of cytokeratin 20 expression in pancreatic and colorectal cancer

AU - Wildi, Stefan

AU - Kleeff, Jörg

AU - Maruyama, Haruhisa

AU - Maurer, Christoph A.

AU - Friess, Helmut

AU - Büchler, Markus W.

AU - Lander, Arthur D.

AU - Korc, Murray

PY - 1999/10

Y1 - 1999/10

N2 - Cytokeratin 20 belongs to the epithelial subgroup of the intermediate filament family. Because of its restricted range of expression in humans, it has become an important tool for detecting and identifying metastatic cancer cells by immunohistochemistry and by PCR analysis. Despite its widespread diagnostic use in colorectal cancer and occasional use in pancreatic cancer, little is known about the expression of CK 20 in these tumors in vivo. Therefore, in the present study we characterized CK 20 expression in pancreatic and colorectal cancer by comparison with its expression in the normal pancreas and colon. Tissue samples from 24 patients with pancreatic cancer and from 41 patients with colorectal cancer were examined for CK 20 expression by Northern blot analysis, immunohistochemistry, and in situ hybridization. CK 20 expression was observed in the cancer cells of both cancer types. A subgroup of the pancreatic cancers exhibited a 3.2-fold increase in CK 20 mRNA by comparison with respective normal controls. In contrast, colon cancers underexpressed CK 20 mRNA by comparison with the respective controls. In the normal tissues, CK 20 immunoreactivity was relatively faint and sparse in the pancreatic ductal cells but intense and abundant in the apical portions of the colonic mucosa. CK 20 immunoreactivity was also evident in the ductal cells from the chronic pancreatitis-like lesions adjacent to the cancer cells. Furthermore, distant metastases from pancreas carcinomas exhibited strong CK 20 immunoreactivity. It is concluded that CK 20 is overexpressed in pancreatic cancer and that it can serve as an excellent marker for metastatic pancreatic cancer.

AB - Cytokeratin 20 belongs to the epithelial subgroup of the intermediate filament family. Because of its restricted range of expression in humans, it has become an important tool for detecting and identifying metastatic cancer cells by immunohistochemistry and by PCR analysis. Despite its widespread diagnostic use in colorectal cancer and occasional use in pancreatic cancer, little is known about the expression of CK 20 in these tumors in vivo. Therefore, in the present study we characterized CK 20 expression in pancreatic and colorectal cancer by comparison with its expression in the normal pancreas and colon. Tissue samples from 24 patients with pancreatic cancer and from 41 patients with colorectal cancer were examined for CK 20 expression by Northern blot analysis, immunohistochemistry, and in situ hybridization. CK 20 expression was observed in the cancer cells of both cancer types. A subgroup of the pancreatic cancers exhibited a 3.2-fold increase in CK 20 mRNA by comparison with respective normal controls. In contrast, colon cancers underexpressed CK 20 mRNA by comparison with the respective controls. In the normal tissues, CK 20 immunoreactivity was relatively faint and sparse in the pancreatic ductal cells but intense and abundant in the apical portions of the colonic mucosa. CK 20 immunoreactivity was also evident in the ductal cells from the chronic pancreatitis-like lesions adjacent to the cancer cells. Furthermore, distant metastases from pancreas carcinomas exhibited strong CK 20 immunoreactivity. It is concluded that CK 20 is overexpressed in pancreatic cancer and that it can serve as an excellent marker for metastatic pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0032694993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032694993&partnerID=8YFLogxK

M3 - Article

C2 - 10537351

AN - SCOPUS:0032694993

VL - 5

SP - 2840

EP - 2847

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -